Could a new drug heal bleeding ulcers faster? trial pits tegoprazan against lansoprazole
NCT ID NCT07708545
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This trial compares two medicines—tegoprazan and lansoprazole—for healing bleeding stomach ulcers. Adults with bleeding peptic ulcers receive one of the two drugs daily for 14 days, along with standard care like IV fluids and a stomach exam. A second exam after treatment checks which drug leads to better ulcer healing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tegoprazan and lansoprazole
- What this could lead to
- If tegoprazan works better, it could become a new standard treatment for healing bleeding stomach ulcers faster and more effectively.
- What could go wrong
- This is a Phase 2 trial with 162 participants, so results are preliminary. The drug may not prove superior to the existing treatment, and individual responses can vary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEPTIC ULCER BLEEDING are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
RSUD Balaraja
Tangerang, Banten, 15610, Indonesia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
RSUP Dr. M. Djamil
Padang, West Sumatra, 25129, Indonesia
Contact Phone: •••-•••-••••
Contact
-
RSUPN Dr. Cipto Mangunkusumo
Jakarta Pusat, DKI Jakarta, 10430, Indonesia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.